Xu Chun Hua, Xue Jin Shan, Zhang Xiu Wei, Yu Li Ke, Lin Yong
Endoscopic Center of Nanjing Chest Hospital, Nanjing, Jiangsu 210029, China.
Clinical Center of Nanjing Respiratory Diseases and Imaging, Nanjing, Jiangsu 210029, China.
Clin Respir J. 2018 Apr;12(4):1473-1478. doi: 10.1111/crj.12693. Epub 2017 Sep 14.
Macrophage inhibitory cytokine-1 (MIC-1), a transforming growth factor-β superfamily cytokine, is involved in tumor pathogenesis, and its measurement can be used as a clinical tool for the diagnosis of a wide range of cancers.
The aim of this study was to explore the diagnostic value of serum MIC-1 in patients with solitary pulmonary nodules (SPNs).
Serum specimens from 158 malignant SPN patients, 110 benign SPN patients, along with 120 healthy volunteers. The levels of serum MIC-1 were measured by sandwich enzyme-linked immunosorbent assay.
Serum levels of MIC-1 in malignant SPN patients were significantly higher than those in benign SPN patients (P < .01), or those in healthy volunteers (P < .01). With a cutoff of 685.8 pg/ml, the sensitivity and specificity of MIC-1 in differentiating between malignant SPN patients and benign SPN patients, and between malignant SPN patients and healthy volunteers was, 56.3% and 92.7%, and 65.8% and 96.7%, respectively. An area under the curve (AUC) for malignant SPN resulting from MIC-1, which was significantly better than any other tumor markers tested including carbohydrate antigens 12-5 (CA125), and carcinoembryonic antigen (CEA).
In conclusion, measurement of serum MIC-1 levels could be considered as a diagnostic biomarker for malignant SPN patients.
巨噬细胞抑制细胞因子-1（MIC-1）是一种转化生长因子-β超家族细胞因子，参与肿瘤发病机制，其检测可作为多种癌症诊断的临床工具。
本研究旨在探讨血清MIC-1在孤立性肺结节（SPN）患者中的诊断价值。
收集158例恶性SPN患者、110例良性SPN患者以及120例健康志愿者的血清标本。采用夹心酶联免疫吸附测定法检测血清MIC-1水平。
恶性SPN患者血清MIC-1水平显著高于良性SPN患者（P <.01），也显著高于健康志愿者（P <.01）。以685.8 pg/ml为临界值，MIC-1区分恶性SPN患者与良性SPN患者以及恶性SPN患者与健康志愿者的敏感性和特异性分别为56.3%和92.7%，以及65.8%和96.7%。MIC-1检测恶性SPN的曲线下面积（AUC）显著优于包括糖类抗原12-5（CA125）和癌胚抗原（CEA）在内的其他任何检测的肿瘤标志物。
总之，血清MIC-1水平检测可被视为恶性SPN患者的诊断生物标志物。
